Get started
JOHNSON DRNJOHNSON DRNJOHNSON DRN

JOHNSON DRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

JNJB34 trade ideas

JNJ Road Ahead20171017 - Product Pipeline "apalutamide (ARN-509) - Prostate cancer pre-metastatic castration-resistant" - Phase III 20171221 - U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer Apalutamide is an investigational, next-generation oral androgen receptor inhibitor that inhibits the action of androgen in prostate cancer cells, and prevents binding of androgen to the androgen receptor, and translocation of the androgen receptor to the nucleus of the cancer cell. 20180118 - with Pfizer in hot pursuit, JNJ loses a critical patent fight as it scrambles for a new prostate cancer drug OK If J&J loses this battle, it still has a late-stage drug in front of the FDA — apalutamide, or ARN-509 — it’s hoping can protect the big revenue stream it gets from Zytiga (abiraterone), an oral drug that has helped revolutionize prostate cancer treatment over the last 5 years. J&J won a priority review of apalutamide for nonmetastatic castration resistant prostate cancer, an early designation. And it’s fielding Phase III data that is slated to be revealed at the ASCO Genitourinary Cancers Symposium on February 8. The accelerated PDUFA date is in April.
NYSE:JNJLong
by ParCorn
JOHNSON & JOHNSON PULL BACK TO SUPPORT OF ITS TRIANGLE-LONGJ&J STOCK, AFTER BREAKS UP A TRIANGLE PATTERN IS PULLING BACK TO SUPPORT AT 137.25, WHICH GIVE A GOOD OPPORTUNITY TO ENTER . I AM EXPECTING THE STOCK HOLDS AT SUPPORT AND BOUNCE. THE INITIAL TARGET COULD BE 145, WHICH IS THE 200% OF FIBONACCI EXTENSION OF THE PREVIOUS LOW. HOWEVER, THE TRIANGLE CALL FOR A LONG TERM TARGET OF 151-152 MINIMUM. IF THE STOCK PRICE BREAKS SUPPORT DOWN FOR A GOOD MARGIN, THE STOP LOSS IS SET UP AT 134. THIS ANALYSIS IS FOR EDUCATION PURPOSES. GOOD LUCK!!!! www.tradingview.com
NYSE:JNJLong
by ralvizua
Stocks that have raised dividends for at least 25 Years11/18/17 - JNJ has been on a majestic bullish power trend since 03/09. You can't be anything but bullish long-term. If we were trying to time the market or at least get a better price, we might want to wait for a 10% pullback to the most recent pivot high of 123-126ish from August 2016. If that area of 123-126 is taken out I would be more bearish than bullish with the next lower target area of 109-113ish. As a strong fundamental company that has increased dividends every year for 54 straight years and is stable during a recession, this is a great company to own for your portfolio. Current Forward Dividend & Yield is 3.36 (2.37%).
NYSE:JNJLong
by ArtPeirce